Defiance Daily Target 2X Long LMND ETF and Health Sciences Acquisitions Co. 2 Compared

A critical review of the risk, volatility, and financial performance of these two finance companies.

Apr. 18, 2026 at 12:10pm

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy machinery components in muted metallic tones, representing the complex financial systems and mechanisms that drive the performance of investment products.A detailed, industrial-style illustration captures the complex financial infrastructure underlying the performance of these two investment vehicles.NYC Today

A comparative analysis of the Defiance Daily Target 2X Long LMND ETF and Health Sciences Acquisitions Co. 2 reveals stark differences in risk, volatility, institutional ownership, and financial metrics. The Defiance ETF has significantly higher volatility and revenue compared to the acquisition company.

Why it matters

This review provides valuable insights for investors considering these two finance-related investments, highlighting the Defiance ETF's higher risk profile but stronger financial performance compared to the more stable Health Sciences Acquisitions Co. 2.

The details

The Defiance Daily Target 2X Long LMND ETF has a beta of 9.67, meaning its share price is 867% more volatile than the S&P 500. In contrast, Health Sciences Acquisitions Co. 2 has a beta of 0.09, making its share price 91% less volatile than the broader market index. Institutional investors own the majority of shares in both companies, at 87.8% for Defiance and 89.7% for Health Sciences Acquisitions. However, insiders hold a larger stake in Health Sciences Acquisitions at 21.9% compared to 6.6% for Defiance.

  • The analysis was published on April 18, 2026.

The players

Defiance Daily Target 2X Long LMND ETF

An exchange-traded fund that provides 2x leveraged exposure to the Lemonade Inc. stock.

Health Sciences Acquisitions Co. 2

A special purpose acquisition company (SPAC) focused on the biopharma and medical technology sectors in North America and Europe.

Got photos? Submit your photos here. ›

The takeaway

Investors considering these two finance-related investments should carefully weigh the Defiance ETF's higher risk and volatility against its stronger financial performance, while also evaluating the more stable but less proven Health Sciences Acquisitions Co. 2.